AgomAb Therapeutics NV insider David R Epstein purchases $103,500 in AGMB shares
The director paid an average of $6.90 a share, according to a Form 4 filed with the SEC on Nov 6.
A Form 4 filed on Nov 6 shows David R Epstein (Director) buying 15,000 AgomAb Therapeutics NV shares worth $103,500 on Nov 5.
The purchase was made in the open market, not through an award, an option exercise or a plan. The trade was reported within two business days, as Section 16 requires.
The purchase raises the insider's holding by 60%, to 40,000 shares.
Details from the SEC filing:
| Company | AgomAb Therapeutics NV (AGMB) |
|---|---|
| Insider | David R Epstein |
| Role | Director |
| Transaction | Open-market purchase (code P) |
| Shares | 15,000 |
| Average price | $6.90 |
| Value | $103,500 |
| Trade date | Nov 5, 2026 |
| Filed with the SEC | Nov 6, 2026, 6:39 AM ET |
| Shares held after | 40,000 |
| Ownership | Direct |
| Rule 10b5-1 plan | Not marked in the filing |
Open the full breakdown of this AGMB trade
See earlier insider stories on AgomAb Therapeutics NV · See the biggest insider trades of each day
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.
